Expression of Hepatitis B Virus Surface Antigens Containing Pre-s Regions by Recombinant Vaccinia Viruses

  • Bernard Moss
  • Kuo-Chi Cheng
  • Geoffrey L. Smith
Part of the Applied Virology Research book series (AOTP, volume 1)


Hepatitis B is a major problem throughout the world. Approximately 200 million people are chronically infected with hepatitis B virus (HBV), and numerous deaths result from fulminant hepatitis, cirrhosis, and primary hepatocellular carcinoma. The 42-nm blood-borne infectious particle is composed of a nucleocapsid and a lipoprotein envelope. During acute infections as well as in chronic carrier states, excess envelope protein, hepatitis B virus surface antigen (HBsAg), is secreted into the blood as 22-nm empty particles. The latter have been purified and used as a subunit vaccine. Despite the efficacy and safety of the plasma-derived product, the high cost associated with purification and testing and the limited quantities available have prevented extensive use of the vaccine in areas of the world where hepatitis B is highly endemic. For these reasons, alternative methods of producing HBsAg are being developed. Genetic engineering has been used to produce HBsAg in yeast and mammalian cells (reviewed by Tiollais et al., 1985), offering the possibility of a more widely available recombinant vaccine. Nevertheless, the requirement for extensive protein purification, refrigerated storage of the vaccine, and a schedule of repeated inoculations may still impose limits on the global use of HBV vaccine for the immediate future.


Vaccinia Virus Thymidine Kinase Recombinant Virus Recombinant Vaccinia Virus Smallpox Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Chakrabarti, S., Brechling, K., and Moss, B. (1985). Mol. Cell. Biol. 5, 3403–3409.PubMedGoogle Scholar
  2. Cheng, K.-C., and Moss, B. (1987). J. Virol 61, 1286–1290.PubMedGoogle Scholar
  3. Cheng, K.-C., Smith, G. L., and Moss, B. (1986). J. Virol. 60, 337–344.PubMedGoogle Scholar
  4. Mackett, M., Smith, G. L., and Moss, B. (1982). Proc. Natl. Acad. Sci. USA 79, 7415–7419.PubMedCrossRefGoogle Scholar
  5. Mackett, M., Smith, G. L., and Moss, B. (1984). J. Virol. 49, 857–864.PubMedGoogle Scholar
  6. Milich, D. R., McNamara, M. K., McLachlan, A., Thornton, G. B., and Chisari, F. V. (1985). Proc. Natl. Acad. Sci. USA 82, 8168–8172.PubMedCrossRefGoogle Scholar
  7. Moss, B., Smith, G. L., Gerin, J. L., and Purcell, R. H. (1984). Nature (Lond.) 311, 67–69.CrossRefGoogle Scholar
  8. Moss, B. (1985). In Virology (B. N. Fields, D. M. Knipe, R. M. Chanock, J. Melnick, B. Roizman, and R. Shope, eds.), pp. 685–703, Raven Press, New York.Google Scholar
  9. Panicali, D., and Paoletti, E. (1982). Proc. Natl. Acad. Sci. USA 79, 4927–4931.PubMedCrossRefGoogle Scholar
  10. Smith, G. L., Mackett, M., and Moss, B. (1983). Nature (Lond.) 302, 490–495.CrossRefGoogle Scholar
  11. Tiollais, P. C., Pourcell, C., and Dejean, A. (1985). Nature (Lond.) 317, 489–495.CrossRefGoogle Scholar
  12. Valenzuela, P., Coit, D., and Kuo, C. H. (1985). Biotechnology 3, 317–320.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • Bernard Moss
    • 1
  • Kuo-Chi Cheng
    • 2
  • Geoffrey L. Smith
    • 3
  1. 1.Laboratory of Viral Diseases, National Institute of Allergy and Infectious DiseasesNational Institutes of HealthBethesdaUSA
  2. 2.Department of PediatricsCornell University Medical CollegeNew YorkUSA
  3. 3.Department of PathologyUniversity of CambridgeCambridgeEngland

Personalised recommendations